Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

by Vandana Singh, Benzinga Editor

July 1, 2021 11:23 AM | 1 min read | Make a Comment

Ault Global Holdings Inc DPW, a diversified holding company, has announced that Alzamend Neuro Inc ALZN has submitted an investigational new drug application to the FDA for a Phase 1 study of AL001.
The Phase 1 study is designed to determine clinically safe and appropriate AL001 dosing in future studies.
AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia-related to mild, moderate, and severe cognitive impairment associated with Alzheimer's disease.
After completing this initial study, Alzamend said it intends to initiate a Phase 1/2a trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AL001 in Alzheimer's disease.
ALZN Price Action: ALZN shares were trading down 9.04% at $7.95 at last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Small Cap FDA Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.